You are here

Servier

Servier’s vorasidenib proves efficacy in tumor growth reduction

Servier’s vorasidenib proves efficacy in tumor growth reduction

Clinical Trials Arena

clinical trials

Flag link:

Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS

Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS

BioSpace

Flag link:

FDA starts speedy review of Servier's Tibsovo in MDS

FDA starts speedy review of Servier's Tibsovo in MDS

Pharmaphorum

priority reviews

Flag link:

ASCO: French Pharma's Drug Slows Tumors in Brain Cancer Patients

ASCO: French Pharma's Drug Slows Tumors in Brain Cancer Patients

BioSpace

Flag link:

Servier adds a 'smile' to its brand while setting ambitious oncology goals

Servier adds a 'smile' to its brand while setting ambitious oncology goals

Endpoints

corporate branding

Flag link:

ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe

ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe

Fierce Pharma

Flag link:

Servier Phase III colorectal cancer trial fails to meet primary endpoint

Servier Phase III colorectal cancer trial fails to meet primary endpoint

Pharmafile

colorectal cancer

clinical trials

Flag link:

Servier cans autism hope bumetanide after phase 3 fails

Servier cans autism hope bumetanide after phase 3 fails

Pharmaforum

autism spectrum disorder

clinical trials

Flag link:

With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer

With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer

Fierce Pharma

bile duct cancer

Flag link:

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal

Pharmaforum

Flag link:

Precision reacquires rights to allogeneic CAR-Ts from Servier

Precision reacquires rights to allogeneic CAR-Ts from Servier

Fierce Biotech

Precision Biosciences

allogeneic cells

Flag link:

Agios, changing its identity, to sell cancer drug business to Servier

Agios, changing its identity, to sell cancer drug business to Servier

BioPharma Dive

Agios Pharmaceuticals

Flag link:

Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics

Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics

Endpoints

Celsius Therapeutics

colorectal cancer

Flag link:

Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal

Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal

Fierce Biotech

osteoarthritis of the knee

clinical trials

Flag link:

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

BioPharma Dive

clinical trials

Omecamtiv Mecarbil

cardiovascular disease

Flag link:

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

AP

Flag link:

Trial of Amgen, Servier’s heart failure drug clears interim check

Trial of Amgen, Servier’s heart failure drug clears interim check

PM Live

chronic heart failure

Omecamtiv Mecarbil

clinical trials

Flag link:

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

Endpoints

Flag link:

Servier reveal how they are using data to empower their field force

Servier reveal how they are using data to empower their field force

Pharmaforum

Flag link:

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

Pharmaceutical Business Review

Flag link:

Pages